drugset / Trial / NCT03525405

A Study to Evaluate the Mass Balance of 14C-Napabucasin in Healthy Adult Male Subjects

NCT03525405

Phase 1 Completed 8 enrolled Sumitomo Pharma America, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase I, single-center, open-label, single-sequence, study evaluating the absorption, metabolism, and excretion of napabucasin in healthy adult male volunteers using a mixture 14C-radiolabeled and unlabeled material.

Timeline

Start
2018-05-18
Primary completion
2018-06-02
Completion
2018-06-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Napabucasin Small molecule 240 mg

Indications

No indication recorded.